ATC codes: N06AB03
Depressive disorders ICD11 code: 6A9Z
Medicine type
Chemical agent
List type
Oral > Solid: 20 mg (as hydrochloride)
EML status history
First added in 2007 (TRS 946)
Changed in 2007 (TRS 950)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)
Adolescents and adults
Therapeutic alternatives
citalopram (ATC codes: N06AB04)
escitalopram (ATC codes: N06AB10)
fluvoxamine (ATC codes: N06AB08)
paroxetine (ATC codes: N06AB05)
sertraline (ATC codes: N06AB06)
Patent information
Patents have expired in most jurisdictions
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the deletion of fluoxetine for the treatment of depressive disorders in children from the complementary list of the EMLc. The Committee accepted that fluoxetine may be used in children younger than 12 years in some setting where there is limited access to mental health facilities and non-pharmacological interventions and may be recommended in some consensus guidelines. However, the Committee noted that the reported prevalence of depression in children younger than 12 years is low and considered that the current evidence for use of fluoxetine in this age group was inconclusive and insufficient to support its ongoing inclusion the EMLc. This recommendation therefore also applies to the listing of fluoxetine on the EMLc in Section 2.3 Medicines for other common symptoms in palliative care. The Committee noted that the prevalence of depression substantially increases throughout adolescence and into adulthood and confirmed that fluoxetine will remain included on the EML for the treatment of depression in adults.